Meckler Jeffrey A 4
4 · Travere Therapeutics, Inc. · Filed Sep 30, 2024
Insider Transaction Report
Form 4
Meckler Jeffrey A
Director
Transactions
- Exercise/Conversion
Common Stock
2024-09-30$10.48/sh+40,000$419,200→ 121,000 total - Exercise/Conversion
Stock option (right to buy)
2024-09-30+40,000→ 0 totalExercise: $10.48Exp: 2024-10-08→ Common Stock (40,000 underlying) - Sale
Common Stock
2024-09-30$14.06/sh−40,000$562,324→ 81,000 total
Footnotes (3)
- [F1]This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.
- [F2]The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The stock option is fully vested and exercisable.